)
Brian Tomkowicz
VP, Scientific Strategy & Innovation,
SK pharmteco
Brian Tomkowicz, PhD, is Vice President, Scientific Strategy & Innovation at SK pharmteco, where he leads internal vector engineering efforts across AAV, lentiviral, and adenoviral platforms, as well as manufacturability assessment and platform development for commercial manufacturing. He has more than 15 years of biotech and pharmaceutical experience, including nearly a decade at Janssen, where he helped establish internal gene therapy and viral production capabilities. An accomplished cell and molecular biologist, Brian focuses on advancing scalable, robust viral vector technologies to support the development and delivery of next-generation cell and gene therapies.
Sessions
-
04-May-2026Next-generation gene therapy manufacturing to drive better in vivo outcomes: Improving vector quality and delivery efficiency to reduce dose requirements, improve safety, and achieve greater scalability
-
08-Sep-2026Next Generation Vector Engineering and Delivery Topic: From ex vivo complexity to in vivo delivery: what will it take to manufacture lentiviral vectors for the next generation of cell therapy?